New drug KT-579 enters first human tests – no disease, just safety check
NCT ID NCT07412288
First seen Feb 18, 2026 · Last updated Jun 11, 2026 · Updated 25 times
Summary
This early-stage study is testing a new oral drug, KT-579, in 96 healthy adults to see if it is safe and how the body handles it. Participants receive either the drug or a placebo. The goal is to gather safety data, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Celerion
RECRUITINGLincoln, Nebraska, 68502, United States
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.